Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy

Bischof, Antje; Manigold, Tobias; Barro, Christian; Heijnen, Ingmar; Berger, Christoph; Derfuss, Tobias; Kühle, Jens; Daikeler, Thomas

doi:10.1136/annrheumdis-2017-212045

Cited by 60 publications

(65 citation statements)

References 10 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a correlation between sNfL levels and axonal damage assessed with NCS in CIDP patients starting IT (Figure ) in line with previous findings of sNfL levels being a reflection of neuro‐axonal damage . The correlation in our study was, however, no longer significant when corrected for age, which may be explained by the relatively small number of NCS.…”

Section: Discussionsupporting

confidence: 91%

“…We found a correlation between sNfL levels and axonal damage assessed with NCS in CIDP patients starting IT (Figure 2) in line with previous findings of sNfL levels being a reflection of neuro-axonal damage. 10,[16][17][18][19][20][21] The correlation in our study was, however, no longer significant when corrected for age, which may be explained by the relatively small number of NCS. We used the electrophysiological data from NCS performed in our center to exclude variation in CMAP measurements due to local differences in measurement protocols and equipment, which limited the number of patients available for this analysis.…”

Section: Snfl As a Biomarker For Axonal Damagecontrasting

confidence: 88%

“…Overall, sNfL levels measured in CIDP patients in our study were lower compared to patients with vasculitic neuropathy or amyotrophic lateral sclerosis, 17,21 in which axonal degeneration is one of the hallmarks of the disease, and higher compared to patients with inherited neuropathies, who have a very slow rate of axonal degeneration. 23 However, direct comparison of sNfL levels between studies should be done with caution, as age distribution and methods of included in this study were comparable to that of the healthy control cohort previously published by our laboratory, ruling out any storage or shipment effects on our test results.…”

Section: Snfl As a Biomarker For Axonal Damagecontrasting

confidence: 56%

See 2 more Smart Citations

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy

Lieverloo

Wieske

Verhamme

et al. 2019

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

Axonal damage in chronic inflammatory demyelinating polyneuropathy (CIDP) is the main predictor of poor outcome. We hypothesized that serum neurofilament light chain (sNfL) reflects disease activity by detecting ongoing neuro‐axonal damage in CIDP. Three prospective cohorts of CIDP patients were studied: (a) patients starting induction treatment (IT cohort, N = 29) measured at baseline and 6 months after starting treatment; (b) patients on maintenance treatment (MT) starting intravenous immunoglobuline (IVIg) withdrawal (MT cohort, N = 24) measured at baseline and 6 months after IVIg withdrawal or at time of relapse; and (c) patients in long‐term remission without treatment (N = 27). A single molecule array assay was used to measure sNfL. Age‐matched healthy controls (N = 30) and age‐specific reference values were used for comparison. At baseline, sNfL was higher in patients starting IT compared to healthy controls. Ten out of 29 IT (34%) patients have sNfL levels above the 95th percentile of age‐specific cut‐off values. In the MT and remission cohort, elevated sNfL levels were infrequent and not different from healthy controls. sNfL levels were correlated with electrophysiological markers of axonal damage. At follow‐up assessment, patients with active disease (non‐responders and patients who relapsed after IVIg withdrawal) had higher sNfL levels compared with patients with stable disease (responders and patients who were successfully withdrawn from IVIg treatment). sNfL levels were increased in a third of CIDP patients starting IT and reflected axonal damage. sNfL levels might be usable as biomarker of disease activity in a subset of CIDP patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Snfl As a Biomarker For Axonal Damagecontrasting

confidence: 88%

Section: Snfl As a Biomarker For Axonal Damagecontrasting

confidence: 56%

See 1 more Smart Citation

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy

Lieverloo

Wieske

Verhamme

et al. 2019

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

show abstract

“…The acquired neuropathies have also been the focus of NF studies. Serum NF-L is elevated in polyneuropathies as diverse as chronic inflammatory demyelinating polyneuropathy, anti-MAG neuropathy, and vasculitic neuropathy [10,11]. Serum levels were not only elevated compared to healthy controls but also seemed to decline with remission [11] and to correlate with disease severity and outcome [10].…”

Section: Peripheral Neuropathymentioning

confidence: 99%

Neurofilaments: The C-Reactive Protein of Neurology

et al. 2020

View full text Add to dashboard Cite

Neurofilaments (NFs) are quickly becoming the biomarkers of choice in the field of neurology, suggesting their use as an unspecific screening marker, much like the use of elevated plasma C-reactive protein (CRP) in other fields. With sensitive techniques being readily available, evidence is growing regarding the diagnostic and prognostic value of NFs in many neurological disorders. Here, we review the latest literature on the structure and function of NFs and report the strengths and pitfalls of NFs as markers of neurodegeneration in the context of neurological diseases of the central and peripheral nervous systems.

show abstract

“…96 Leukocytosis, anemia, RF, ANA, and decreased complement are suggestive of SVN, but also nonspecific. 105 Recently, serum neurofilament light chains (sNfL) 108 and elevated VEGF 103,104 have been shown to predict vasculitic neuropathy. In particular, sNfL predicted vasculitic neuropathy with a sensitivity of 82% and specificity of 100%, and appeared to correlate with disease activity.…”

Section: Nonsystemic Vasculitic Neuropathymentioning

confidence: 99%

Vasculitic Neuropathies

2019

View full text Add to dashboard Cite

Vasculitic neuropathies are disorders that result from inflammation in the peripheral nerves' vascular supply, resulting in ischemic injury. These disorders may be a result of systemic inflammation or may be confined to the peripheral nervous system. Causative etiologies include primary systemic vasculitis, vasculitis secondary to other conditions such as primary connective tissue disorders, infectious, paraneoplastic, and drug-induced conditions, and nonsystemic vasculitic neuropathy. Early recognition and treatment of these conditions is imperative to prevent substantial morbidity and mortality. The goal of this review is to provide an organization of the vasculitic neuropathies and an overview of principles of diagnosis and treatment for the clinical neurologist.

show abstract

Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy

Cited by 60 publications

References 10 publications

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy

Neurofilaments: The C-Reactive Protein of Neurology

Vasculitic Neuropathies

Contact Info

Product

Resources

About